Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05665595 · ClinicalTrials.gov registry record · Phase 3
A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)
A Phase 3 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,594
- Enrollment target
NCT05665595 is a Phase 3 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 1,594 participants.
The verdict
NCT05665595, a Phase 3 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,594 participants
- Enrollment target
Study Summary
The primary purpose of this study is to compare pembrolizumab/vibostolimab to pembrolizumab with respect to recurrence-free survival (RFS). The primary hypothesis is that pembrolizumab/vibostolimab is superior to pembrolizumab with respect to RFS as assessed by the investigator in participants with high-risk resected Stage IIB, IIC, III and IV melanoma.
Interventions
- BIOLOGICAL Pembrolizumab
- BIOLOGICAL Pembrolizumab/Vibostolimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,594 participants |
| Start Date | 2023-01-19 |
| Est. Completion | 2025-09-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05665595
The ClinicalTrials.gov registry entry for NCT05665595 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,594 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT05665595 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05665595 about?
NCT05665595 is a clinical study titled "A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)". The primary purpose of this study is to compare pembrolizumab/vibostolimab to pembrolizumab with respect to recurrence-free survival (RFS). The primary hypothesis is that pembrolizumab/vibostolimab is superior to pembrolizumab with respect to RFS as assessed by the investigator in participants with ...
What is the current status of trial NCT05665595?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,594 participants. The study started on 2023-01-19. Estimated completion is 2025-09-26.
What interventions are being tested in trial NCT05665595?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Pembrolizumab/Vibostolimab (BIOLOGICAL).
Who is sponsoring clinical trial NCT05665595?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.